We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563344

CAS#: 150661-91-9

Description: NC1153 is a blocker of IL-2-induced activation of JAK3 and its downstream substrates STAT5a/b. It acts by promoting long-term allograft survival and sparing the recipient from multiple toxicities.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-10-30. Prices are subject to change without notice.

NC1153 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 563344
Name: NC1153
CAS#: 150661-91-9
Chemical Formula: C18H36N2O
Exact Mass: 296.2828
Molecular Weight: 296.49
Elemental Analysis: C, 72.92; H, 12.24; N, 9.45; O, 5.40

Synonym: NC1153; NC-1153; NC 1153; CN-1153; CN 1153; CN1153;

IUPAC/Chemical Name: 2,12-Bis[(dimethylamino)methyl]-cyclododecanone


InChi Code: InChI=1S/C18H36N2O/c1-19(2)14-16-12-10-8-6-5-7-9-11-13-17(18(16)21)15-20(3)4/h16-17H,5-15H2,1-4H3


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Martinez GS, Ross JA, Kirken RA. Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors. Clin Cancer Drugs. 2016;3(2):131-137. doi: 10.2174/2212697X03666160610085943. PubMed PMID: 29046866; PubMed Central PMCID: PMC5642970.

2: Nagy ZS, Ross JA, Rodriguez G, Bader J, Dimmock J, Kirken RA. Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways. FEBS Lett. 2010 Apr 16;584(8):1515-20. doi: 10.1016/j.febslet.2010.02.071. Epub 2010 Mar 6. PubMed PMID: 20211620; PubMed Central PMCID: PMC2854231.

3: Nagy ZS, LeBaron MJ, Ross JA, Mitra A, Rui H, Kirken RA. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. Mol Cancer. 2009 Aug 26;8:67. doi: 10.1186/1476-4598-8-67. PubMed PMID: 19709433; PubMed Central PMCID: PMC2741462.

4: Thompson JE. JAK protein kinase inhibitors. Drug News Perspect. 2005 Jun;18(5):305-10. Review. PubMed PMID: 16193102.

5: Stepkowski SM, Kao J, Wang ME, Tejpal N, Podder H, Furian L, Dimmock J, Jha A, Das U, Kahan BD, Kirken RA. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol. 2005 Oct 1;175(7):4236-46. PubMed PMID: 16177063.

6: Podder H, Kahan BD. Janus kinase 3: a novel target for selective transplant immunosupression. Expert Opin Ther Targets. 2004 Dec;8(6):613-29. PubMed PMID: 15584866.